Published in Antimicrob Agents Chemother on October 24, 2016
Discovery of a Novel Antifungal Agent in the Pathogen Box. mSphere (2017) 0.75
Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev (2002) 17.58
Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev (2007) 15.66
Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet (1984) 11.51
Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother (2003) 7.09
Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother (2002) 4.52
Invasive Candidiasis. N Engl J Med (2015) 4.18
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis (2015) 4.07
A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat Protoc (2008) 3.46
In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother (2002) 2.60
The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett (2002) 2.50
Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog (2010) 2.09
Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol (2007) 1.99
In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother (2003) 1.85
Our current understanding of fungal biofilms. Crit Rev Microbiol (2009) 1.79
An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov (2010) 1.78
Fungal biofilm resistance. Int J Microbiol (2012) 1.73
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol (2012) 1.27
The transcriptional regulator Nrg1p controls Candida albicans biofilm formation and dispersion. Eukaryot Cell (2010) 1.16
Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. Expert Opin Drug Discov (2013) 1.03
Resistance of Candida spp. to antifungal drugs in the ICU: where are we now? Intensive Care Med (2014) 1.02
Biofilm formation is a risk factor for mortality in patients with Candida albicans bloodstream infection-Scotland, 2012-2013. Clin Microbiol Infect (2015) 1.01
High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors. Antimicrob Agents Chemother (2013) 0.96
Invasive Candidiasis. Infect Dis Clin North Am (2015) 0.92
Update on Antifungal Drug Resistance. Curr Clin Microbiol Rep (2015) 0.87
In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms. Antimicrob Agents Chemother (2013) 0.86
A Novel Small Molecule Inhibitor of Candida albicans Biofilm Formation, Filamentation and Virulence with Low Potential for the Development of Resistance. NPJ Biofilms Microbiomes (2015) 0.85
Effect of silver nanoparticles on Candida albicans biofilms: an ultrastructural study. J Nanobiotechnology (2015) 0.84
SQ109, a new drug lead for Chagas disease. Antimicrob Agents Chemother (2015) 0.82
High-content phenotypic screenings to identify inhibitors of Candida albicans biofilm formation and filamentation. Pathog Dis (2014) 0.82
Targeting Candida albicans filamentation for antifungal drug development. Virulence (2016) 0.82
High Throughput Screening Identifies Novel Lead Compounds with Activity against Larval, Juvenile and Adult Schistosoma mansoni. PLoS Negl Trop Dis (2016) 0.81
Structure-activity relationships of antitubercular salicylanilides consistent with disruption of the proton gradient via proton shuttling. Bioorg Med Chem (2012) 0.80
Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi. Virulence (2016) 0.80
In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis. Antimicrob Agents Chemother (2015) 0.78
Screening Repurposing Libraries for Identification of Drugs with Novel Antifungal Activity. Antimicrob Agents Chemother (2020) 0.75